Reprogramming the Diabetic Wound Microenvironment by Enzyme Cascade-Driven, ROS-Responsive Microspheres
ACS Biomaterials Science & Engineering · 2026
DOI: 10.1021/acsbiomaterials.6c00663 ↗Kurz gefasst
Fachartikel in der Zeitschrift ACS Biomaterials Science & Engineering, 2026. Verfasst von Cong Ma und 4 weiteren Autor:innen. Beteiligte Einrichtung: School of Food Science and Engineering, South China University of Technology, 381 Wushan Road, Guangzhou, Guangdong 510640, China. Hauptthemen laut MEDLINE: Microspheres, Wound Healing, Reactive Oxygen Species, Curcumin. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 69 Literaturangaben. Gefördert von: Basic and Applied Basic Research Foundation of Guangdong Province, Higher Education Discipline Innovation Project, National Basic Research Program of China (973 Program).
Abstract (Originalsprache)
Diabetes represents a major global health burden, and diabetic wounds remain particularly challenging due to delayed healing and high infection risk. A dysregulated wound microenvironment, characterized by hyperglycemia, excessive reactive oxygen species (ROS), and persistent hypoxia, critically impairs angiogenesis and tissue regeneration. Herein, we report a multifunctional microsphere system integrating ROS-responsive curcumin-loaded nanoparticles, glucose oxidase (GOx), and catalase (CAT) to simultaneously regulate glucose, oxygen, and oxidative stress in diabetic wounds. The microsphere system reduces glucose levels through a GOx-mediated oxidation process, generating hydrogen peroxide (H2O2), which is subsequently decomposed by CAT into oxygen, thereby alleviating local hypoxia. Notably, excessive ROS—particularly H2O2—are not only scavenged but also repurposed as an endogenous oxygen source, enabling sustained oxygen supplementation at the wound site. Meanwhile, ROS-responsive curcumin-loaded nanoparticles enable on-demand drug release in oxidative environments, providing localized antioxidant and anti-inflammatory effects while avoiding premature drug exposure. As a result, the system exhibits efficient glucose reduction, oxygen generation, and ROS scavenging, leading to enhanced angiogenesis, fibroblast migration, and accelerated wound healing. Histological and immunohistochemical analyses further confirm reduced inflammation, increased vascularization, and improved tissue regeneration, with the Cur/Enzyme/Nanoclay@Microsphere formulation demonstrating the most pronounced therapeutic efficacy. Overall, this work presents a promising strategy for diabetic wound management by restoring wound microenvironment homeostasis through coordinated enzymatic cascades and ROS-responsive drug delivery.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Food Science and Engineering, South China University of Technology, 381 Wushan Road, Guangzhou, Guangdong 510640, China.
- Institute of Chemistry of New Materials, National Academy of Sciences of Belarus, 36F. Skaryna str., Minsk 220141, Belarus.
ORCID-Profile: Lijun You
Förderung
- Basic and Applied Basic Research Foundation of Guangdong Province
- Higher Education Discipline Innovation Project
- National Basic Research Program of China (973 Program)
Zitieren
APA
Ma, C., Chen, Y., Zong, Z., You, L., & Hileuskaya, K. (2026). Reprogramming the Diabetic Wound Microenvironment by Enzyme Cascade-Driven, ROS-Responsive Microspheres. ACS Biomaterials Science & Engineering. https://doi.org/10.1021/acsbiomaterials.6c00663
Vancouver
Ma C, Chen Y, Zong Z, You L, Hileuskaya K. Reprogramming the Diabetic Wound Microenvironment by Enzyme Cascade-Driven, ROS-Responsive Microspheres. ACS Biomaterials Science & Engineering. 2026. doi:10.1021/acsbiomaterials.6c00663
BibTeX
@article{Ma2026,
author = {Ma, Cong and Chen, Yifan and Zong, Zihao and You, Lijun and Hileuskaya, Kseniya},
title = {Reprogramming the Diabetic Wound Microenvironment by Enzyme Cascade-Driven, ROS-Responsive Microspheres},
journal = {ACS Biomaterials Science & Engineering},
year = {2026},
doi = {10.1021/acsbiomaterials.6c00663}
}
EUVIMED